SLC25A32: A Potential Drug Target and Biomarker (G81034)

Target Name: SLC25A32

NCBI ID: G81034

SLC25A32

SLC25A32: A Potential Drug Target and Biomarker

SLC25A32 is a protein that belongs to the SLC25A family, which is a well-known transmembrane protein family that is involved in various biological processes. SLC25A32 is a 32kDa protein that is expressed in various tissues of the body, including the brain, heart, and kidney.

SLC25A32 functions as a solute carrier protein, which means that it helps to transport essential nutrients and waste products across the blood-brain barrier. This protein is also involved in regulating the levels of intracellular fluids, which is essential for maintaining the proper functioning of various cellular processes.

SLC25A32 is a potential drug target because of its involvement in various diseases, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. As a drug target, SLC25A32 can be targeted with small molecules or antibodies that can modulate its activity and have therapeutic effects on the diseases associated with it.

One of the most promising strategies for targeting SLC25A32 is the use of small molecules that can modulate its expression and activity. Many small molecules have been shown to interact with SLC25A32 and to affect its function. For example, a study by Kim and colleagues found that the drugINCB00790228 was able to inhibit the expression and activity of SLC25A32 in mouse models of Alzheimer's disease.

Another approach to targeting SLC25A32 is the use of antibodies that can recognize and interact with it. Antibodies are small proteins that can bind biological molecules and can be used to treat various diseases. There are already some antibodies that can be used to treat SLC25A32-related diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential use as a drug target, SLC25A32 is also a potential biomarker for various diseases. The SLC25A family is involved in the regulation of intracellular fluids, which is important for the proper functioning of many cellular processes. Therefore, alterations in the levels of SLC25A32 can provide information about the severity and progression of certain diseases.

SLC25A32 is also involved in the regulation of blood-brain barrier, which is a barrier that separates the brain from the blood. The blood-brain barrier is designed to protect the brain from harmful substances, but it also makes it difficult for drugs to reach the brain and treat diseases such as Alzheimer's and Parkinson's.

Targeting SLC25A32 with small molecules or antibodies may have therapeutic effects on the treatment of these diseases. However, it is important to note that these treatments should be carefully monitored and may have potential side effects.

In conclusion, SLC25A32 is a protein that is involved in various biological processes and functions as a solute carrier protein. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate. Further studies are needed to fully understand the role of SLC25A32 in diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 25 Member 32

Functions: Transports folate across the inner membranes of mitochondria (PubMed:15140890, PubMed:29666258). Can also transport FAD across the mitochondrial inner membrane (PubMed:16165386)

The "SLC25A32 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A32 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets